Abstract
Objectives
Enterococcus faecalis is a gram positive diplococci, highly versatile and a normal commensal of the gut microbiome. Resistance to vancomycin is a serious issue in various health-care setting exhibited by vancomycin resistant Enterococci (VRE) due to the alteration in the peptidoglycan synthesis pathway. This study is thus aimed to detect the VRE from the patients with root caries from the clinical isolates of E. faecalis and to evaluate the in-silico interactions between vanA and the Aegles marmelos bio-compounds.
Methods
E. faecalis was phenotypically characterized from 20 root caries samples and the frequency of vanA and vanB genes was detected by polymerase chain reaction (PCR). Further crude methanolic extracts from the dried leaves of A. marmelos was assessed for its antimicrobial activity. This is followed by the selection of five A. marmelos bio-compounds for the computational approach towards the drug ligand interactions.
Results
12 strains (60%) of E. faecalis was identified from the root caries samples and vanA was detected from two strains (16%). Both the stains showed the presence of vanA and none of the strains possessed vanB. Crude extract of A. marmelos showed promising antibacterial activity against the VRE strains. In-silico analysis of the A. marmelos bio-compounds revealed Imperatonin as the best compound with high docking energy (–8.11) and hydrogen bonds with < 140 TPSA (Topological polar surface area) and zero violations.
Conclusion
The present study records the VRE strains among the root caries with imperatorin from A. marmelos as a promising drug candidate. However the study requires further experimentation and validation.
Keywords: E. faecali, vanA, vanB, A. marmelos, health, environment
INTRODUCTION
Enterococci, which belong to the Group D Streptococci, are Gram-positive facultative aerobic bacteria that occur as oval pairs or short chains. Enterococci are generally regarded as normal flora of the gut, the oral microbiome, and the vagina. However, they are associated with a variety of recalcitrant nosocomial infections, especially urinary tract infections [1]. Enterococcus faecalis (E. faecalis) is also reported to be an important dental pathogen that causes root caries and is associated with dental procedures that cause endocarditis. Enterococci are the second most common infectious health challenge in the U.S., and in India, they are the most frequently isolated species (63.8%) [2]. Enterococci have recently attracted renewed attention because of their propensity to develop multidrug resistance against routinely used antibiotics, including vancomycin. In addition to intrinsic resistance, acquired resistance through chromosomes, plasmids, or transposons is also common. The exceptional ability of these strains to transmit genetic information between themselves and to other genera has conferred them with a high level of vancomycin resistance [3].
Multidrug-resistant enterococci have emerged as serious infections worldwide, especially vancomycin-resistant Enterococci (VRE), which have rapidly emerged in healthcare settings in recent decades. VRE were identified as hospital-associated pathogens in Europe in the mid-1980s and have since spread worldwide [4]. The drug resistance mechanism of VRE is mainly encoded by vanA and vanB gene clusters, which are most commonly found in Enterococcus faecium and are becoming widespread worldwide [5]. The resistance mechanism of VRE involves alterations in peptidoglycan synthesis, which is mediated by a cluster of van genetic determinants. The vanA gene cluster induces resistance to vancomycin and teicoplanin (the vanA phenotype) and is mostly associated with various types of Tn1546 transposon variants. Alterations may be caused by point mutations, deletions, or activation of insertion sequences [6]. In E. faecalis, the host Inc18 and pheromone-responsive families of plasmids, which are only found in this species, have been associated with vanA genetic determinants [7]. VRE dynamics are influenced by mobile genetic elements that carry vanA Tn1546 insertion point heterogeneity, and also by clonal proliferation of various stains that acquire vanA [8].
1. Literature review
Targeting the vanA gene could be an effective strategy for combating drug-resistant strains of E. faecalis. Multidrug-resistant strains, such as VRE, might pose serious risks for hospitalized patients. A systematic review and meta-analysis associated VRE with high infection rates [9]. Thus, alternative treatment strategies involving the use of various plants and herbs, and their bioactive compounds are becoming popular in various developing countries, including India. Of the numerous natural herbs from India, Aegle marmelos (A. marmelos), commonly known as the ‘wood apple plant’, which belongs to the family Rutaceae, is known to possess various bioactive properties [10]. Phytochemical analyses of the various parts of A. marmelos have identified tannins, phenylpropanoids, flavonoids, carotenoids, and other minor compounds as possessing promising bioactive properties [11]. Various studies have shown that biocompounds extracted from A. marmelos using various methods might possess multiple therapeutic effects [12]. Indeed, the antibacterial effects of the various solvent extracts have exhibited promising properties against various Gram-positive and Gram-negative bacteria [13].
However, there are no recent reports on the antimicrobial effects of A. marmelos against drug-resistant E. faecalis strains. Here, we aimed to determine the antimicrobial effects of a methanolic crude extract from A. marmelos against VRE isolated from root caries. Because bioinformatic analysis of biocompounds to identify their targets can accelerate drug development [14], we used computational tools to evaluate potential drug–ligand interactions between the compounds, coumarin, xanthotoxol, imperatorin, aegeline, and marmeline, which were isolated from A. marmelos, against vanA.
MATERIALS AND METHODS
1. Sampling and isolation of E. faecalis
This prospective observational study was conducted from April 2022 to June 2022 at the Department of Microbiology at Saveetha Dental College and Hospitals. Carious scrapings excavated from twenty individuals with typical root caries were collected in sterile trypticase soy broth and immediately transferred to the microbiology lab. The reconstituted samples were then streaked onto sterile Brain Heart Infusion Agar (HiMedia Laboratories, Mumbai, India) and then incubated at 37℃ for 24 hours. Typical colonies were then identified and subjected to preliminary gram staining and routine biochemical tests to identify E. faecalis strains. Ethical approval for the study was granted by the institutional ethics review board (approval numbers: SRB/SDC/UG-2073/21/MICRO/061 and IHEC/SDC/UG-2073/21/MICRO/602).
2. Antibiotic susceptibility test
Antibiogram profiling of the clinical strains of E. faecalis was done using the standard agar, Kirby–Bauer disc diffusion method [15]. Next, lawn cultures of the fresh broth suspension of E. faecalis were established on sterile Mueller–Hinton agar (HiMedia Laboratories, Mumbai, India). The following antibiotics were selected based on the 2021 CLSI guidelines and introduced on the lawn surface at indicated concentrations, viz., Amoxyclav (30 µg), ceftriazone (30 µg), cefoperazone–sulbactam (75/30 µg), clindamycin (2 µg), cefixime (5 µg), levofloxacin (5 µg), linezolid (30 µg) vancomycin (30 µg), azithromycin (15 µg), amikacin, tetracyclin (30 µg), ciprofloxacin (5 µg), cefoperazone (2 µg), and gentamycin (10 µg). Vancomycin E-strips were used to identify MIC breakpoints for VRE selection. All plates were incubated at 37℃ for 24 hours, followed by zone of inhibition measurements.
3. PCR detection of vanA and vanB in E. faecalis
Fresh vancomycin-resistant clinical isolates were recovered from sterile trypticase soy agar cultures after 24 hours of incubation at 37℃, followed by genomic DNA extraction using a Qiagen kit (Germany) following the manufacturer’s protocol. Specific primers (Table 1) were added to the master mix followed by PCR on a thermocycler (Biorad Laboratories) to detect the presence of the genetic determinants of interest. The PCR program involved 35 cycles at an annealing temperature of 58℃. The PCR product alongside a 1.5 kb DNA ladder, was then subjected to 1% agarose gel electrophoresis, followed by ethidium bromide staining and visualization using a gel documentation system.
Table 1.
The primers used for the study to detect vanA and vanB genetic determinants from the clinical isolates of VRE
| Gene of target | Primers used for the study | Annealing temperature | Amplicon size |
|---|---|---|---|
| vanA | F: 5’-TCTGCAATAGAGATAGCCGC-3’ R: 5’-GGAGTAGCTATCCCAGCATT-3’ |
58℃ | 400 bp |
| vanB | F: 5’-ATGGGAAGCCGATAGTC-3’ R: 5’-GATTTCGTTCCTCGACC-3’ |
58℃ | 635 bp |
4. Preparation of the A. marmelos extract
The crude A. marmelos extract was prepared as described previously [16], with slight modifications. Fresh A. marmelos (L.) Correa was obtained from local regions, washed thrice with sterile distilled water, and then shade-dried before grinding the leaves into fine powder. Next, 100 g of the A. marmelos dried leaf powder were mixed with 100 mL of methanol. The resulting suspension was then allowed to react for a week at room temperature, on an orbital shaker (Remi Lab World). The extract was then filtered into sterile Petri dishes using a Whatman No. 1 filter paper and then evaporated. The extracts were then stored at 4℃ until use (Fig. 1).
Figure 1.
The schematic representation of the A. marmelos crude extraction procedure.
5. Analysis of the antimicrobial effect of the A. marmelos extract
The crude extract recovered from the methanol was weighed to determine the final yield. Next, the extracts were weighed and dissolved in dimethyl sulphoxide at final concentrations of 100, 50, 25, 12.5, and 6.25 mg/mL. Fresh clinical strains of VRE were prepared as broth suspension and was made as a lawn onto sterile brain heart infusion agar and the wells were cut using agar puncture [17]. Next, 50 µL of the diluted extract were added into appropriate wells, followed by incubation at 37℃ for 24 hours. After the incubation, the zone of clearance was measured and recorded. The assay was repeated thrice and the results were recorded as mean values.
6. Modeling and validation of the VanA protein structure
Because the crystal structure of VanA was unavailable in the protein data bank, SWISS-MODEL was used to predict its structure using the bacterial RQC complex 7AQC-Q chain from Bacillus subtilis as a template. The quality of the predicted model was then validated by assessing its residues in the favored regions using Ramachandran plots and was selected for the docking analysis.
7. Ligand preparation and optimization
The structural configurations of the bioactive derivatives were visualized using the ChemSketch software. The following A. marmelos biocompounds were selected for optimization and further interaction analysis: coumarin, xanthotoxol, imperatorin, aegeline, marmeline, and erythromycin. Next, selected ligands were saved as MOL files using the Open-Babel molecular converter and then saved in PDB format.
8. Assessment of the drug properties of the selected biocompounds
The Molinspiration program was used to analyze the log P molecular descriptors for partition coefficient, compound molecular weight, and the hydrogen bond acceptor and donor counts associated with membrane permeability and bioavailability. Next, the absorption, distribution, metabolism, and elimination characteristics of the selected biocompounds were evaluated using “Lipinski’s rule of five”.
9. Analysis of docking interactions
Docking analysis of the affinity between each compound (coumarin, xanthotoxol, imperatorin, aegeline, marmeline, and erythromycin) and A. marmelos’ vanA gene was done using the AutoDock tool. Grid maps were used to embed the vanA protein using an auxiliary Autogrid program, one for each type of atom present in the complex being docked. To model the hydrogen bonds and van der Waals forces, Lennard–Jones parameters of 12-10 and 12-6 were used, respectively. The force fields were evaluated in two phases and the intramolecular energetics from unbound states and bound conformations were assessed using the following equation: ∆G = ∆Gvdw + ∆Ghbond + ∆Gelec + ∆Gtor + ∆Gdesolv. Discovery Studio Visualizer was used to visualize hydrogen bonds between coumarin, xanthotoxol, imperatorin, aegeline, marmeline, or erythromycin and the E. faecalis vanA gene.
RESULTS
1. VRE phenotypic characterization and detection of the vanA gene
E. faecalis was identified and isolated from 12 strains (60%) based on its typical pinpoint colonies on trypticase soy agar plates. Gram staining revealed typical Gram-positive diplococci, which were bile esculin test positive and catalase test negative (Fig. 2). Seven multi-drug resistant isolates (58.3%) were identified using the disc diffusion method, whereas two strains (16%) were vancomycin-resistant (VRE strains). PCR analysis revealed that both VRE strains carried the vanA gene (amplicon size: 400 bp, Fig. 3), but not the vanB gene.
Figure 2.
Phenotypic characterization of E. faecalis from the clinical samples (a) E. faecalis growth on blood agar (b) Gram staining showing gram positive diplococcic (c) positive bile esculin test (d) catalase tested negative.
Figure 3.
Electropherogram of vanA gene product of size 400 bp in lanes 1 and 2 with 1.5 k bp marker lane (M).
2. Antimicrobial effect of the A. marmelos extract against VRE
The methanol extraction method yielded 23 mg of extract from 100 g of A. marmelos dry leaf powder. The extract exhibited promising effects against both the multidrug-resistant strains (n = 7) and the VRE strains possessing the vanA gene (n = 2), with a zone size of 12 mm at a concentration of 100 mg/mL, although lower concentrations (50, 25, 12.5, and 6.25 mg/mL) had no effect (Fig. 4).
Figure 4.
Antimicrobial effect of the crude methanolic extracts at varying concentrations (100 mg, 50 mg, 25 mg, 12.5 mg and 6.25 mg) of A. marmelos against the VRE strains of E. faecalis.
3. Validation of VanA protein structure
The E. faecalis VanA protein entry was retrieved from Uniprot (ID: Q0WYK7). Because the VanA protein structure was not available on PDB, it was modeled using the 7AQC-Q chain template. The quality of the predicted model was regarded as being good because 90.6% of the residues were in the most favored regions, whereas only 0.3% of the residues occurred in disallowed regions (Fig. 5).
Figure 5.
Prediction of vanA structure and homology modelling in Swissmodel Server and validation of the predicted structure using Ramachandran plot.
4. Assessments of the structures and drug properties of A. marmelos bioactive compounds
Successful optimization of the selected ligands was attained using the ChemSketch software. The three-dimensional structures of coumarin, xanthotoxol, imperatorin, aegeline, marmeline, and erythromycin were obtained and their PubChem IDs and molecular weights are presented in Fig. 6.
Figure 6.
The 3D structures of the selected bio-compounds (a) Coumarin, (b) Xanthotoxol, (c) Imperatorin, (d) Aegeline, (e) Marmeline from A. marmelos and (f) Erythromycin (control) with the Pubchem ID and molecular weight.
5. Evaluation of drug-likeness parameters
The predictions of the bioactivity of coumarin, xanthotoxol, imperatorin, aegeline, marmeline, or erythromycin against E. faecalis vanA protein were determined using default parameter settings, and the predicted scores are shown in Tables 1 and 2.
Table 2.
The drug properties of the selected bio-compounds from A. marmelos
| Compound name | nViolations | TPSA (Ǻ) | Rotatable bonds | Hydrogen bond donor | Hydrogen bond acceptor | miLogP | Volume | N atoms |
|---|---|---|---|---|---|---|---|---|
| Coumarin | 0 | 30.21 | 0 | 0 | 2 | 2.01 | 128.59 | 11 |
| Xanthotoxol | 0 | 63.58 | 0 | 1 | 4 | 2.00 | 162.16 | 15 |
| Imperatorin | 0 | 52.59 | 3 | 0 | 4 | 3.95 | 240.47 | 20 |
| Aegeline | 0 | 58.56 | 6 | 2 | 4 | 2.64 | 281.45 | 22 |
| Marmeline | 0 | 58.56 | 8 | 2 | 4 | 4.32 | 342.23 | 26 |
| Erythromycin | 2 | 193.92 | 7 | 5 | 14 | 2.28 | 709.28 | 51 |
6. Analysis of the docking between the compounds from A. marmelos and the E. faecalis VanA protein
After the docking analysis, suitable conformers were selected using the Lamarckian Genetic Algorithm. The ball and stick models of hydrogen bond interactions between coumarin, xanthotoxol, imperatorin, aegeline, marmeline, or erythromycin and the E. faecalis VanA protein were visualized using Accelrys Discovery Studio (Fig. 7). The number of hydrogen bonds formed in concert with the torsional energy and the scores after the docking between the drug and ligands (Table 3).
Figure 7.
Visualizing hydrogen interactions between vanA with (a) coumarin (b) xanthotoxol (c) imperatorin (d) aegeline (e) marmeline (f) erythromycin.
Table 3.
The docking scores of the bio-compounds from A. marmelos against vanA protein of E. faecalis
| EfbA docking with compounds | Number of hydrogen bonds | Binding energy | Inhibition constant | Ligand efficiency | Intermolecular energy | vdW + Hbond + desolv energy | Electrostatic energy | Torsional energy | Total internal unbound |
|---|---|---|---|---|---|---|---|---|---|
| Coumarin | 1 | –5.99 | 41.01 | –0.546 | –5.99 | –5.96 | –0.03 | 0.0 | 0.0 |
| Xanthotoxol | 3 | –7.14 | 31.4 | –0.41 | –6.44 | –6.33 | –0.11 | 0.3 | –0.44 |
| Imperatorin | 3 | –8.11 | 5.85 | –0.48 | –7.44 | –7.4 | –0.03 | 0.03 | –0.03 |
| Aegeline | 3 | –7.69 | 2.31 | –0.35 | –9.78 | –9.26 | –0.52 | 2.09 | –1.21 |
| Marmeline | 0 | –6.56 | 15.46 | –0.25 | –9.25 | –9.18 | –0.07 | 2.68 | –1.78 |
| Erythromycin | 5 | –7.87 | 1.7 | –0.15 | –10.26 | –10.01 | –0.25 | 2.39 | –4.23 |
DISCUSSION
E. faecalis is an important oro-dental pathogen and its virulence factors are vital for the establishment of infections [18]. Our analyses indicated that the frequency of E. faecalis in patients with root caries is 60%, and detected the presence of the vanA gene in VRE strains. This frequency seems to be higher when compared with earlier studies that detected E. faecalis in 19% and 38%, with statistical significance [19]. This discrepancy may be caused by differences in sample size since our study had a sample size of 20. E. faecalis is frequently found in the apical part of the root canal, implying that its invasion occurs during endodontic therapy [20]. A link has also been reported between the presence of E. faecalis and the number of clinic visits, which are caused by coronal microleakage via the temporary filling used between endodontic treatment sessions [21]. These findings suggest that E. faecalis is more prevalent in patients with dental infections or disorders.
Resistant E. faecalis strains are common in healthcare settings. However, in dental settings, periodic surveillance of multidrug resistance or VRE strains remains limited. This study indicates that the presence of the vanA gene in VRE is up to 16% (n = 2) and did not detect the vanB gene. A previous global report on VRE prevalence in eight countries found the prevalence of VRE to be highest in the UK (2.9%), followed by Israel (2%) [22]. However, VRE rates in the remaining European countries were ≤ 1%. VRE strains with the vanB gene have been isolated in Slovenia, Finland, Sweden, and the UK, and they were found to be most common in Slovenia (2%) [23].
Plant bioactive compounds have the potential to control the complications of various microbial pathogens [24, 25]. In this study, we evaluated the antibacterial activity of a methanol extract from the leaves of A. marmelos. Using disc diffusion assays, similar studies have reported the antimicrobial activities of extracts obtained using chloroform, methanol, and water against Bacillus subtilis, Staphylococcus aureus, Klebsiella pneumoniae, Proteus mirabilis, Escherichia coli, Salmonella paratyphi A, and Salmonella paratyphi B [26]. Here, we report the promising effects of a methanol extract from A. marmelos, which showed significant moderate activity against clinical VRE isolates.
In this study, analysis of docking interactions between the biocompounds and vanA, as well as the docking scores and energies, were evaluated. Because the VanA protein structure was not available, we used SWISS-MODEL to predict its structure using the 7AQC-Q chain template. Using Ramachandran validation, which can evaluate predicted protein structures by showing similar residues in the favored region, we found that in the predicted model, 90.6% of the residues were in the favored region, whereas only 0.3% occurred in disallowed regions. Drug parameter analysis using Molinspiration revealed all the compounds to be the best, with zero violations based on Lipinsky’s rule of five, and that erythromycin (control) had two violations. However, TPSA analysis revealed that the oral bioavailability scores did not exceed 140 Ǻ, except for erythromycin. However, the nuclear receptor and enzyme inhibitor bioactivity scores, with values of > 0.3, were promising.
Analysis of bioactive properties (Table 4) with scores set at > 0.3, revealed promising scores for all A. marmelos ligands that were selected. Studies of the biocompounds obtained from A. marmelos indicate that in lung disorders (edema and fibrosis), imperatorin has anti-inflammatory effects on alveolar macrophages. Coumarin, which has systemic effects, has been reported to eliminate the symptoms of persistent brucellosis. A. marmelos has anti-inflammatory effects against various cancer cell lines and it has been reported to contain the anti-carcinogenic substances, beta caryophyllene and caryophyllene oxide [27]. In this study, the inhibitory property of imperatorin is promising against the E. faecalis VanA protein. A limitation of this study is that we did not purify the crude extract for analyses of the active biocompounds. Future studies should seek to identify novel A. marmelos biocompounds, determine their cytotoxicity, and perform preclinical trials to determine their suitability as alternative treatments for E. faecalis infections. However, this study is the first to suggest the compound imperatorin, from A. marmelos, as a potential drug for treating E. faecalis infections.
Table 4.
The bioactivity scores of the selected compounds based on the score > 0.3
| Compounds | Kinase inhibitor | Nuclear receptor ligand | GPCR ligand | Ion channel modulator | Enzyme inhibitor | Protease inhibitor |
|---|---|---|---|---|---|---|
| Coumarin | –1.57 | –1.42 | –1.44 | –0.86 | –0.58 | –1.43 |
| Xanthotoxol | –0.82 | –0.75 | –0.70 | –0.16 | –0.14 | –0.94 |
| Imperatorin | –0.56 | –0.18 | –0.37 | –0.02 | 0.10 | –0.60 |
| Aegeline | –0.23 | –0.23 | 0.19 | –0.22 | 0.05 | –0.05 |
| Marmeline | –0.28 | 0.15 | 0.16 | –0.14 | 0.13 | –0.05 |
| Erythromycin | –1.25 | –1.12 | –0.50 | –1.31 | –0.60 | –0.18 |
CONCLUSION
This study shows that the vanA gene is frequent in multidrug-resistant E. faecalis strains in a dental health care setting. These findings highlight the need for periodic microbiological surveillance in healthcare settings. Our findings show that the leaves of A. marmelos are effective against E. faecalis VRE strains. Among the five biocompounds selected for analysis, imperatorin exhibits good binding energy, but further studies are required to establish its suitability as an alternative to existing antibiotics.
Funding Statement
FUNDING This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Footnotes
CONFLICTS OF INTEREST
None to declare.
REFERENCES
- 1.Ceci M, Delpech G, Sparo M, Mezzina V, Sánchez Bruni S, Baldaccini B. Clinical and microbiological features of bacteremia caused by Enterococcus faecalis. J Infect Dev Ctries. 2015;9(11):1195–203. doi: 10.3855/jidc.6587. [DOI] [PubMed] [Google Scholar]
- 2.Kayaoglu G, Ørstavik D. Virulence factors of Enterococcus faecalis: relationship to endodontic disease. Crit Rev Oral Biol Med. 2004;15(5):308–20. doi: 10.1177/154411130401500506. [DOI] [PubMed] [Google Scholar]
- 3.Love RM. Enterococcus faecalis--a mechanism for its role in endodontic failure. Int Endod J. 2001;34(5):399–405. doi: 10.1046/j.1365-2591.2001.00437.x. [DOI] [PubMed] [Google Scholar]
- 4.Sahu LS, Dash M, Paty BP, Purohit GK, Chayani N. Enterococcal infections and antimicrobial resistance in a tertiary care hospital, Eastern India. Afro-Egypt J Infect Endem Dis. 2015;5(4):255–64. doi: 10.21608/aeji.2015.17846. [DOI] [Google Scholar]
- 5.Arthur M, Quintiliani R., Jr Regulation of VanA- and VanB-type glycopeptide resistance in enterococci. Antimicrob Agents Chemother. 2001;45(2):375–81. doi: 10.1128/AAC.45.2.375-381.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Ben Yahia H, Chairat S, Hamdi N, Gharsa H, Ben Sallem R, Ceballos S, et al. Antimicrobial resistance and genetic lineages of faecal enterococci of wild birds: emergence of vanA and vanB2 harbouring Enterococcus faecalis. Int J Antimicrob Agents. 2018;52(6):936–41. doi: 10.1016/j.ijantimicag.2018.05.005. [DOI] [PubMed] [Google Scholar]
- 7.Zirakzadeh A, Patel R. Vancomycin-resistant enterococci: colonization, infection, detection, and treatment. Mayo Clin Proc. 2006;81(4):529–36. doi: 10.4065/81.4.529. [DOI] [PubMed] [Google Scholar]
- 8.Haenni M, Saras E, Châtre P, Meunier D, Martin S, Lepage G, et al. vanA in Enterococcus faecium, Enterococcus faecalis, and Enterococcus casseliflavus detected in French cattle. Foodborne Pathog Dis. 2009;6(9):1107–11. doi: 10.1089/fpd.2009.0303. [DOI] [PubMed] [Google Scholar]
- 9.Willems RPJ, van Dijk K, Vehreschild MJGT, Biehl LM, Ket JCF, Remmelzwaal S, et al. Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis. Lancet Infect Dis. 2023;23(6):719–31. doi: 10.1016/S1473-3099(22)00811-8. [DOI] [PubMed] [Google Scholar]
- 10.Sabu MC, Kuttan R. Antidiabetic activity of Aegle marmelos and its relationship with its antioxidant properties. Indian J Physiol Pharmacol. 2004;48(1):81–8. [PubMed] [Google Scholar]
- 11.Venthodika A, Chhikara N, Mann S, Garg MK, Sofi SA, Panghal A. Bioactive compounds of Aegle marmelos L., medicinal values and its food applications: a critical review. Phytother Res. 2021;35(4):1887–907. doi: 10.1002/ptr.6934. [DOI] [PubMed] [Google Scholar]
- 12.Rahman S, Parvin R. Therapeutic potential of Aegle marmelos (L.)-an overview. Asian Pac J Trop Dis. 2014;4(1):71–7. doi: 10.1016/S2222-1808(14)60318-2. [DOI] [Google Scholar]
- 13.Kothari S, Mishra V, Bharat S, Tonpay SD. Antimicrobial activity and phytochemical screening of serial extracts from leaves of Aegle marmelos (Linn.) Acta Pol Pharm. 2011;68(5):687–92. [PubMed] [Google Scholar]
- 14.Sogasu D, Girija ASS, Gunasekaran S, Priyadharsini JV. Molecular characterization and epitope-based vaccine predictions for ompA gene associated with biofilm formation in multidrug-resistant strains of A.baumannii. In Silico Pharmacol. 2021;9(1):15. doi: 10.1007/s40203-020-00074-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Gupta V, Singla N, Behl P, Sahoo T, Chander J. Antimicrobial susceptibility pattern of vancomycin resistant enterococci to newer antimicrobial agents. Indian J Med Res. 2015;141(4):483–6. doi: 10.4103/0971-5916.159309. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Meena RK, Pareek A, Meena RR. Antimicrobial activity of Aegle marmelos (Rutaceae) plant extracts. Int J MediPharm Res. 2016;2(1):1–5. [Google Scholar]
- 17.Sassone LM, Fidel RA, Murad CF, Fidel SR, Hirata R., Jr Antimicrobial activity of sodium hypochlorite and chlorhexidine by two different tests. Aust Endod J. 2008;34(1):19–24. doi: 10.1111/j.1747-4477.2007.00071.x. [DOI] [PubMed] [Google Scholar]
- 18.Priyadharsini VJ, Smilinegirija AS, Paramasivam A. Enterococcus faecalis an emerging microbial menace in dentistry-an insight into the in-silico detection of drug resistant genes and its protein diversity. J Clin Diagn Res. 2018;12(10):6–10. doi: 10.7860/jcdr/2018/36480.12155. [DOI] [Google Scholar]
- 19.Dahms RA, Johnson EM, Statz CL, Lee JT, Dunn DL, Beilman GJ. Third-generation cephalosporins and vancomycin as risk factors for postoperative vancomycin-resistant Enterococcus infection. Arch Surg. 1998;133(12):1343–6. doi: 10.1001/archsurg.133.12.1343. [DOI] [PubMed] [Google Scholar]
- 20.Nair PN, Henry S, Cano V, Vera J. Microbial status of apical root canal system of human mandibular first molars with primary apical periodontitis after "one-visit" endodontic treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;99(2):231–52. doi: 10.1016/j.tripleo.2004.10.005. [DOI] [PubMed] [Google Scholar]
- 21.Siren EK, Haapasalo MP, Ranta K, Salmi P, Kerosuo EN. Microbiological findings and clinical treatment procedures in endodontic cases selected for microbiological investigation. Int Endod J. 1997;30(2):91–5. doi: 10.1111/j.1365-2591.1997.tb00680.x. [DOI] [PubMed] [Google Scholar]
- 22.Croughan S, O'Cronin D, O'Brien D, Roberts F, Underwood S, O'Connell J, et al. Vancomycin-resistant enterococci in patients attending for colonoscopy: an estimate of community prevalence. Ir Med J. 2022;115(8):649. [PubMed] [Google Scholar]
- 23.Bourgeois-Nicolaos N, Moubareck C, Mangeney N, Butel MJ, Doucet-Populaire F. Comparative study of vanA gene transfer from Enterococcus faecium to Enterococcus faecalis and to Enterococcus faecium in the intestine of mice. FEMS Microbiol Lett. 2006;254(1):27–33. doi: 10.1111/j.1574-6968.2005.00004.x. [DOI] [PubMed] [Google Scholar]
- 24.Sarojini KS, Arivarasu L, SmilineGirijaA S. Herbal formulation: review of efficacy, safety, and regulations. Int J Res Pharm Sci. 2020;11(SPL3):1506–10. doi: 10.26452/ijrps.v11iSPL3.3467. [DOI] [Google Scholar]
- 25.S V, Chaly PE, Girija S, R R, K P, Priyadharsini V. Antimicrobial activity of gotukola leaves and neem leaves - a comparative invitro study. J Ayurveda Holist Med. 2015;3(3):11–5. [Google Scholar]
- 26.Poonkothai M, Saravanan M. Antibacterial activity of Aegle marmelos against leaf, bark and fruit extracts. Anc Sci Life. 2008;27(3):15–8. [PMC free article] [PubMed] [Google Scholar]
- 27.Benni JM, Jayanthi MK, Suresha RN. Evaluation of the anti-inflammatory activity of Aegle marmelos (Bilwa) root. Indian J Pharmacol. 2011;43(4):393–7. doi: 10.4103/0253-7613.83108. [DOI] [PMC free article] [PubMed] [Google Scholar]